Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term randomized-withdrawal maintenance study of extended-release guanfacine in children and adolescents with ADHD
2009-018161-12Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Continue guanfacine hydrochloride with Withdraw to placebo (2 arms). Primary endpoint: Treatment failure during the double-blind randomized-withdrawal phase. Started Aug 2010; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2009-018161-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018161-12.